Advertisement

Volume 1, Issue 17

 

Cover Image

Cover Figure: The immunosuppressive ligand PD-L1 is abundantly expressed by Hodgkin/Reed-Sternberg cells and infiltrating immune cells in classic Hodgkin lymphoma. Brown staining with immunohistochemistry identifies the PD-L1 protein. See the article by Duffield et al.

WASHINGTON, July 25,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

 

In an Exceptional Case Report, Wright and Brown et al describe a patient with primary mediastinal B-cell lymphoma successfully treated with nivolumab who developed severe neutropenia, highlighting a potential complication of this novel therapy.

Seaman and Ragni discuss an exceptional case of a patient with hemophilia where sequential bypassing agent therapy was used to prevent surgical bleeding in a patient with a high-titer inhibitor.

 

Patients with treatment-related acute myeloid leukemia (AML) or those cases evolving from prior hematological disorders are known to have a poor prognosis. Boddu et al further characterize these high-risk patients and argue that they should be considered as a distinct subset of AML patients for future clinical trial designs.

Checkpoint inhibitors such as anti–PD-1 and anti–PDL-1 are new drugs for the treatment of a broad array of malignancies with significant activity in the treatment of patients with Hodgkin lymphoma (HL). However, some patients respond better than others. Duffield et al, studied a series of patients with Epstein-Barr virus (EBV)–positive and –negative HL, highlighting the importance of the interleukin-23 (IL-23)/IL-17 axis in EBV-negative HL patients, which could lead to new therapeutic combinations.

Conditioning for allogeneic transplantation with total lymphoid irradiation and antithymocyte globulin has been associated with reduced risk of acute graft-versus-host disease and transplant-related mortality. In the manuscript by Spinner et al, outcomes are explored with unrelated donors that are fully matched vs those that are 1 antigen mismatched, demonstrating similar outcomes unlike more traditional conditioning approaches. This study highlights the need for analysis of the entire transplant protocol in assessing outcomes.

 


Featured Visual Abstract

Intestinal hephaestin potentiates iron absorption in weanling, adult, and pregnant mice under physiological conditions

Intestinal iron absorption is critical to maintain iron hemostasis. The molecular basis mediating iron uptake is central to enhance our understanding of this important biology and to target critical pathways in disease. In the study by Doguer et al, the role of intestinal hephaestin is explored in weanling, adult, and pregnant mice with interesting findings.

 

 

 

 

Blood Advances is the open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.